07 Jun Revoking drug patents will cost Californians their lives and San Francisco biotech startups their motivation
Howard Dean
San Francisco Examiner, 6/7/2022...
Op-Eds
31 May DOE’s Misuse of Bayh-Dole’s ‘Exceptional Circumstances’ Provision: How Uniform Patent Policies Slip Away
Joseph Allen
IPWatchdog, 5/26/2022 ...
26 May Using Bayh-Dole for cancer drug march-in rights is wrong
David Kappos
Law360, 5/25/2022 ...
26 May Prostate Drug Price Controls Come at Too High a Cost
Craig Garthwaite
RealClearPolicy, 5/26/2022 ...
06 Apr Removing patent rights to lower drug costs is dangerous precedent
Walter G. Copan
Denver Post, 4/6/2022 ...
04 Apr A dubious way to lower drug prices
Richard Parrish
Albany Herald, 4/2/2022 ...
31 Mar Stolen innovation cuts out taxpayers
Stacey Campfield
The Tennessean, 3/31/2022
Also published in Yahoo News, the Knoxville News-Sentinel, and the Commercial Appeal ...
28 Mar There are unintended costs of federal efforts to control drug prices
Lou Berneman
Patriot-News, 3/26/2022 ...
08 Mar When you’re attacking the dead, you’ve hit the bottom of the barrel
Joseph P. Allen
The Hill, 3/8/2022 ...
07 Mar Don’t sacrifice the miracle of American innovation
Niels Reimers
The Mercury News, 3/5/2022
Also published in the East Bay Times and SiliconValley.com ...